Anti-CD95 MoAb (APO-1/Fas) Potentiates the Pro-apoptotic Effect of L-NAME in B-CLL Cells
| Treatment . | % of Apoptotic Cells . | ||
|---|---|---|---|
| Medium . | Anti-CD23 MoAb (10 μg/mL) . | L-NAME (1 mmol/L) . | |
| Control | 2 | 2 | 19 |
| Anti-CD95 MoAb | 3 | 1 | 45 |
| Treatment . | % of Apoptotic Cells . | ||
|---|---|---|---|
| Medium . | Anti-CD23 MoAb (10 μg/mL) . | L-NAME (1 mmol/L) . | |
| Control | 2 | 2 | 19 |
| Anti-CD95 MoAb | 3 | 1 | 45 |
Purified B-CLL cells were resuspended at 1 × 106/mL in RPMI-1640 medium supplemented with 5% FCS and incubated for 48 hours with or without 10 μg/mL of anti-CD23 MoAb (MoAb135) or L-NAME (1 mmol/L) and in the presence or absence of 10 μg/mL of anti-CD95 MoAb (CH-11; Immunotech). At the end of the culture, the percentages of apoptotic cells were determined as previously. Data are from one representative experiment out of three, performed with freshly collected blood samples.